The pharmaceutical industry is almost the only source of new medicines. These are expensive and difficult to discover, and very few of the novel compounds produced reach the market place. Regardless of how good they are, promotion is necessary so that the medical practitioners know about and prescribe them. For doctors who are very busy, and overwhelmed with new information, the promotion must catch their attention and give concise, convincing information. Marketing is relatively easy with a great therapeutic breakthrough, and more difficult if a new drug is only on a par with its competitors.
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In this scenario it is easy to understand the temptations that may face the pharmaceutical companies in seeking ways to capture the attention of prescribers and those involved in purchasing decisions. It is essential for the medicines to generate income to repay the investment and generate funds so that the pharmaceutical companies can function commercially and carry out new lines of research. Temptations include excesses in the contents of advertisements, and inducements such as gifts and hospitality ('freebies') on which much adverse press attention has been focused. Official guidelines make it clear that permissible and fair inducements include organizing information meetings in desirable but not lavish surroundings, providing pens and pads with the name of the product, etc. At the other end ofthe scale there are disallowed practices such as bribery or excessive 'hospitality'. In between are grey areas. Important aims of this meeting were to evaluate the needs of pharmaceutical companies, healthcare professionals and the public for pharmaceutical product promotion and dissemination of information, and how this can be achieved in the best and most acceptable way.
The meeting was well attended, with excellent presentations from various points of view and thoughtful discussion from members of the audience. Dr John Spooner (Medical Director, SterlingWinthrop) spoke on the financial and education needs of the pharmaceutical companies for promotional activity. He first described the component parts of his own company, most of which do not concern pharmaceuticals. Three types of medicine are available from the pharmaceutical division, prescription medicines, generic drugs and over-the-counter products. The profit from prescription medicines is currently 10% of sales. Manufacturing and distribution costs account for 42%, and promotion for 9%; the rest is consumed by administration (17%), and research, development and the medical department (22%). Advertising is needed to increase the usage of a medicine. The 9% for promotion is limited by the Pharmaceutical Price Regulation Scheme, operated with the government using a fairly complex formula. Any spending above this is penalized. About half of the 9% promotion costs pays for representatives and their activities, with advertising including agency fees making up most of the rest. In countries without this sort of control, the proportion of promotion costs to sales is substantially higher (about 20-25%).
Promotion for the generic business accounts for 7% of the total income, whereas the figure is much higher for over-the-counter medicines (33%) in order to compete with other companies and to pay for expensive advertising such as on television.
Besides advertising, pharmaceutical companies need to educate prescribers in the relevant therapeutic areas. Medical information departments and their associated medical advisers help to provide this service, and also to train representatives, answer enquiries, and be responsible for preparing scientific literature on products.
Dr David Jackson (Medical Director, Glaxo Pharmaceuticals UK) talked about types of promotion to the healthcare professions, and changes resulting from needs and pressures. He outlined the main commercial activities for the industry: the representatives, journal advertising, direct mailings, exhibitions, gifts and hospitality. The representative, who is very important in providing information about products, must be well informed and trained in order to interact effectively with highly qualified and skilled practitioners. Although detractors of the pharmaceutical industry criticize representatives, most doctors welcome them, as shown by market research and by the fact that doctors see them by choice and not by obligation. The Code of Practice regulates what representatives say, how they say it, and under what circumstances; it also regulates 'freebies' which are used as reminders of trade names.
Journal advertising is less effective than representation in promotion, and has many pitfalls concerning the Code of Practice. Dr Jackson considered that in the future there will be more emphasis on educational meetings in nonpromotional settings, sponsorship for information technology and screening, and liaison with the new professional managerial positions in the NHS.
Mr John Burton (Managing Director, Milpro Ltd) also spoke about the needs and responses of the medical profession to promotional activities. He thought that whilst the promotional activities of commercial companies are important, their effects are diluted by other factors. The choice by medical practitioner of one form of therapy rather than another is based on a complex range of influences and experience, beginning with their original medical education. Particularly important among the several different communications media used for promotion are personal contact with representatives, meetings, and medical journals.
A survey carried out on 200 GPs by Milpro showed that in 1989 most ofthem saw two to four representatives a week, although a substantial minority saw an The Royal Society of Medicine average of one or less per week, and 4% saw none. Most doctors, when able, saw nearly all representatives, whereas about 5% selected those from some companies and not others. The average GP attended about one pharmaceutical company meeting per month, but 29% attended none over a 3-month period. Although numerous mailings were sent, they were not very important sources of information; many GPs scanned most or all of them but read only a few. Medical video cassettes have recently become more important, and in 1989 GPs saw an average of two medical video cassette recordings with representatives.
Mrs Jean Blake (Principal Pharmacist, North West Thames Regional Drug Information Service) discussed promotional activities to the hospital pharmacist. She felt that development, expansion and innovation in the pharmaceutical industry would continue only if the public and healthcare professionals have confidence in the products. It is in the interest of the patient, the professional involved, and the industry itself, that drug marketing and promotion are ethical and of a high quality. This is by no means always the case, and the popular press has been given many opportunities to exploit failures. The result is a reduced trust of the public and the professionals in modern drug therapy. An aggressive promotion may have a paradoxical effect by making the healthcare professionals think that less promotion would be necessary if the drug is as good as is claimed. Mrs Blake wanted less glossy promotion and more good, reliable information based on sound trials, with genuinely comparative data between different therapies. The UK public generally feel that profit should not be a goal where health is at risk. However, making money and providing benefits to consumers are compatible.
Mrs Helen Wright (Director of Professional Services, Burson-Marsteller) discussed promotional activities to the public. Health care is a political issue, with conflict about whether the responsibility for it lies with doctors, the pharmaceutical industry and the government on one hand, or with the patient on the other. Patients now want to know more about their medical disorders and to play bigger roles in their management. For this they need more knowledge, catered for substantially by the explosion of health matters in the media, and in part by education through patient organizations.
Patient compliance and education are closely linked, and if preventive medicine is to keep health care costs down in the long term, information to the general public will be even more important. The healthcare companies cannot leave this to an unaided press, and there must be a bridge between the scientific jargon and communication to the patient. Knowledge by the patient leads to understanding, belief and compliance. Public relations companies must act as 'honest brokers' for medical information, balancing the commercial aspects with the needs of the media, doctors, patients, and the guidelines of the Medicines Act and the Association of the British Pharmaceutical Industry (ABPl) Code of Practice.
Since healthcare journalists vary in their levels of knowledge, public relations companies need to educate the media in order to function most effectively. It is the poorly educated journalists who produce the Journal of the Royal Society of Medicine Volume 84 September 1991 565 'wonder drug/killer drug' stories that annoy doctors and the pharmaceutical industry, and hinder understanding by patients. 'Media workshops' give medical journalists a thorough background briefing on a particular subject and can provide a context for new, properly informed stories.
Mr David Taylor (King's Fund Institute) addressed the question of how the activities of the pharmaceutical industry should be compared with other industries. British pharmaceutical companies currently spend a total of about £200 million a year on promoting NH8 products, and another £100 million on over-the-counter medicine advertising and other relevant items. The combined sum is rather less than 10% of all UK consumer spending on pharmaceuticals. Figures for other sectors are difficult to compare directly, but overall it appears to be about 3% of revenues on directly identifiable promotion, plus investments in point-of-sale activities (eg in supermarkets, garages, pubs and tobacconists), together with promotional discounting and other purchasing incentives. UK pharmaceutical promotion spending is therefore not markedly out ofline with other sectors, whereas drug companies outside Britain may spend as much as 20% of their income on promotion, compared with only 10% on research.
Factors influencing promotion by the pharmaceutical industry include special legal controls on medicine information, the large number of doctors and pharmacists to be informed, and the wide range of separate, high technology products made. Where there is inadequate patent protection, the companies must rely on promotion to ensure adequate financial return. However, in the world pharmaceutical market there is a danger of investment in promoting poor quality medicines that can harm consumers. Current legislative proposals within the EC to strengthen pharmaceutical patient terms could, and possibly should, be balanced by stronger controls on medicine promotion. Nevertheless, it is important not to erode pharmaceutical innovation and export capability.
Dr Joe Collier (St George's Hospital Medical School) addressed the question of the stage at which promotional activity becomes unacceptable. He said that the drugs industry is the major determinant of medical practice in the UK, and that promotion in many instances has created a biased and often misleading picture of the role of drugs. Although the Medicines Act defines some key promotional controls, it overlooks others and does not reliably implement the controls. The Department of Health has essentially delegated responsibility for the policing of the Act to the industry itself, so weakening the control of marketing. He gave specific examples to illustrate instances of unethical behaviour.
Many members of the audience, who were mainly from the pharmaceutical industry, agreed that improper promotional activities sometimes occur, and cause them great embarrassment. However, these were the exceptions rather than the rule, and most drug companies behave in a highly ethical fashion.
Mr David Massam (Association of British Pharmaceutical Industry) gave the last presentation which discussed whether the Code of Practice was working. There had been 73 complaints in 1989, 70% of which breached the Code. Inter-company complaints formed a substantial percentage of the total. Patient safety was rarely, if ever, prejudiced by errors in promotional material. The number of complaints has been increasing, possibly because the detection rates are getting higher rather than the industry getting worse. The ABPI now gives a lot of publicity to questionable promotion, and it also actively seeks out problems by scrutiny. Mr Massam pointed out that it takes 'two to tango' -doctors are partly to blame for unacceptable practices since some want £30 a time to see representatives, or a book for their library, etc.
The Committee has the power to suspend adverts. Publishing the names of offenders has helped to change attitudes. The Association will be taking a lead in giving good information to the public by publishing a compendium of patient drug package leaflets.
My conclusion about the fundamental issues is that the pharmaceutical industry is the centre for excellent
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There can be few doctors currently practising who do not have some involvement with computers. Rapid advances in 'user friendly' interfaces have lessened the need to know the intricacies of how the machines work. In the next few years, voice input devices may remove any need for keyboard skills. The Computers in Medicine Forum of the RSM grew out of a number of enthusiasts using early microcomputers, and it was remarkable what could be achieved using machines of puny power by today's standards. Now, although the 'how to do it' question is a lot easier and quicker to answer, the question of 'What can I do with it?' is more relevant. The Forum was constituted to provide a means by which clinicians from many different medical specialties can meet to discuss problems and solutions in medical computer applications.
Membership is also open to computer scientists and those with a commercial interest in the field. The fourth meeting of this forum covered a wide variety of computer applications in medicine. Medical audit and data analysis Mr C G Greenough (Consultant Orthopaedic Surgeon from Middlesbrough General Hospital) presented the Windsor computerized coding system for orthopaedic practice. The inadequacies of the ICD and OPCS classifications for clinical use prompted the development of this multi-axial classification of orthopaedic diagnoses and operations. It consists of a six digit code. The first two digits specify anatomical site, the second innovative research and the provision of new medicines. This desirable activity is very expensive, and has to be paid for by sales of products. If we want to have the benefits of that enterprise, the pharmaceutical industry must be allowed to flourish. Promotion and education are essential, and it is in the interests of all concerned that these activities are carried out ethically. Clearly practices outside the bounds of acceptability should, and presumably will, be stopped, but we must not kill the goose that lays the golden egg. As one eminent scientist from the pharmaceutical industry said to me 'the goose that lays the golden egg has warts'. two the main diagnosis or operation, the fifth specifies side, and the sixth more detailed specification. Mapping into OPCS and ICD-9 codes is provided in a commercial development of the system, PANACEA, which can operate as a feeder system for Health Authority programs requiring information coded in this way. Also from Middlesbrough, David Simpson of Teesside Polytechnic showed how two separately developed stand-alone systems were integrated. Their in-house gastrointestinal unit audit information module SENECA was linked with a commercial offthe-shelf operating theatre management system, THEATREMAN. They eliminated duplication of data entry and improved accuracy and speed of communication of operating lists from the gastrointestinal unit to the theatres by means of a dedicated RS232 link and a networking data interchange protocol. In discussion it was agreed that this was important work but far greater investment is needed in developing truly integrated systems. The NHS is a long way behind commercial organizations such as retailers who integrate entire stock control programs from checkout till activity.
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Decision management Mr Michael Edwards (Consultant General Surgeon of Northallerton General Hospital) presented his
Step-Wise Surgery, a new concept in Operation Manuals for theatre use. The system provides a training, teaching and reference tool for the surgical team. Seventy-five general surgical operations have been broken down into detailed numbered steps, considered as a process. The manual is written in a hierarchical outline format on a wordprocessor. This allows shortcuts through the text or amplification as required. Details can be edited to suit individual practice. Different copies, highlighting relevant areas, are produced for trainee surgeons and scrub nurses. Explicit protocols are likely to become increasingly important as part of process audit, and are already being used in quality assurance. 
